# Nanobiomaterial-enabled boron delivery systems and innovative strategies for revolutionizing BNCT

**Authors:** Qiyao Yang, Ruxuan Wang, Huang Lingling, Qiong Bian, Qichun Wei

PMC · DOI: 10.7150/thno.126209 · Theranostics · 2026-02-11

## TL;DR

This review explores how nanobiomaterials can improve boron delivery for BNCT, a promising cancer therapy that combines radiation and targeted drug delivery.

## Contribution

The paper introduces innovative nano-delivery systems and strategies to enhance the precision and effectiveness of boron neutron capture therapy.

## Key findings

- Nano-delivery platforms offer improved boron drug delivery compared to conventional methods.
- Breakthroughs in carrier engineering and targeted strategies enable better tumor targeting.
- Understanding biological factors like the tumor microenvironment is key to designing effective biomaterials.

## Abstract

Boron neutron capture therapy (BNCT) is a novel and emerging form of radiotherapy that combines the advantages of “heavy ion radiotherapy” and “biological targeting”. The therapeutic potential of BNCT is ultimately constrained by precise and efficient delivery of boron drugs. In this review, we systematically trace from conventional boron drugs to sophisticated nano-delivery platforms, emphasizing breakthroughs in carrier engineering, targeted delivery strategies, and multifunctional synergistic systems. A dedicated analysis of the biological foundations, such as cell cycle dynamics, tumor microenvironmental interactions, and immunostimulatory effects, provides a crucial framework for understanding mechanism-informed biomaterial design. By synthesizing current advances with an outlook on future challenges, this work aims to chart a course for translating innovative boron-loaded biomaterials from the laboratory into clinical reality, thereby unlocking the full promise of BNCT.

## Linked entities

- **Chemicals:** boron (PubChem CID 5462311)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, NUCLEOLIN (nucleolin multifunctional protein) [NCBI Gene 4691] {aka C23, NCL, Nsr1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) [NCBI Gene 5366] {aka APR, NOXA}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, Cd47 (CD47 antigen (Rh-related antigen, integrin-associated signal transducer)) [NCBI Gene 16423] {aka 9130415E20Rik, B430305P08Rik, IAP, Itgp}, TAT (tyrosine aminotransferase) [NCBI Gene 6898], RIGI (RNA sensor RIG-I) [NCBI Gene 23586] {aka DDX58, RIG-I, RIG1, RLR-1, SGMRT2}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}, PDC (phosducin) [NCBI Gene 5132] {aka MEKA, PHD, PhLOP, PhLP}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}
- **Diseases:** ovarian, brain, renal, breast, myeloid, and lung malignant tumors (MESH:D010051), oral cancer (MESH:D009062), negative (MESH:D064726), breast cancer (MESH:D001943), hypoxic (MESH:D002534), GBM (MESH:D005909), CPPs (MESH:C565529), RN (MESH:D011832), hemolysis (MESH:D006461), brain tumor (MESH:D001932), Hypoxia (MESH:D000860), liver cancer (MESH:D006528), necrosis (MESH:D009336), triple (MESH:C536008), Death (MESH:D003643), pancreatic tumors (MESH:D010190), inflammatory (MESH:D007249), malignant melanoma (MESH:D008545), glioma (MESH:D005910), metastasis (MESH:D009362), head and neck cancers (MESH:D006258), cytotoxic (MESH:D064420), BNCT (MESH:D016609), cancer (MESH:D009369)
- **Chemicals:** Gd-DOTA (MESH:C050823), Li (MESH:D008094), Fe (MESH:D007501), lipid (MESH:D008055), nucleotide (MESH:D009711), manganese ferrite (MESH:C551151), phthalocyanines (MESH:C013647), nucleoside (MESH:D009705), fructose (MESH:D005632), 18F (MESH:C000615276), tyrosine (MESH:D014443), benzene (MESH:D001554), Gd (MESH:D005682), water (MESH:D014867), phospholipid (MESH:D010743), methotrexate (MESH:D008727), GSH (MESH:D005978), AS1411 (MESH:C513936), borate (MESH:D001881), Mannitol (MESH:D008353), D-glucose (MESH:D005947), Bevacizumab (MESH:D000068258), HA (MESH:D006820), Cy5 (MESH:C085321), Boron nitride (MESH:C017282), Folate (MESH:D005492), ROS (MESH:D017382), galactose (MESH:D005690), Boron (MESH:D001895), PLGA (MESH:D000077182), iron oxide (MESH:C000499), oligonucleotide (MESH:D009841), BODIPY (MESH:C095489), vitamin C (MESH:D001205), copper (MESH:D003300), hydrogen (MESH:D006859), silica (MESH:D012822), DOX (MESH:D004317), PBA (MESH:C010686), chitosan (MESH:D048271), Gd-DTPA (MESH:D019786), boronic-acid (MESH:D001897), Oligosaccharide (MESH:D009844), Oxygen (MESH:D010100), boron-10 (MESH:C000615219), disulfide (MESH:D004220), RGD (MESH:C047981), Porphyrin (MESH:D011166), borane (MESH:D001880), metal (MESH:D008670), 10B (-), sulfur (MESH:D013455), 4He (MESH:D006371), Au (MESH:D006046), CPPs (MESH:D057846), boric acid (MESH:C032688), BPA (MESH:C033685), phenylalanine (MESH:D010649), cetuximab (MESH:D000068818), Trastuzumab (MESH:D000068878)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** GL261 — Mus musculus (Mouse), Mouse glioblastoma, Cancer cell line (CVCL_Y003), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12964131/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12964131/full.md

## References

186 references — full list in the complete paper: https://tomesphere.com/paper/PMC12964131/full.md

---
Source: https://tomesphere.com/paper/PMC12964131